A Case of Pharmacokinetic Interference in Comedication of Clozapine and Valproic Acid

 

 Buy Article Permissions and Reprints

In 4 - 6 % of treatment histories, clozapine induces generalized seizures by reducing the seizure threshold. Despite the knowledge of high risks combined therapy (such as bone marrow suppression, pathological EEG changes), some authors even suggest the prophylactic combination with anticonvulsants in high dose treatment of clozapine. We report a case of a 33-year-old female patient, a heavy smoker, suffering from mixed schizoaffective disorder from 1989 onwards. At her 8th admission in 1998, she was rehospitalized after experiencing her first generalized seizure under clozapine treatment, although no seizure phenomenon or other relevant side-effects under several previous clozapine therapies had been observed. Therefore, she received a valproic acid co-medication during her clozapine therapy. Based on therapeutic drug monitoring of clozapine (weekly) under compliance-controlled conditions, the serum levels of clozapine significantly decreased, probably induced by valproic acid. According to the literature, this case report might support the clinical relevance of therapeutic drug monitoring when clozapine therapy is combined with valproic acid as co-medication.

References

• 1 Bertilsson L, Carrillo J A, Dahl M L, Ilerena A, Alm C, Bondersson U. et al . Clozapine disposition covaries with CYP1 A2 activity determined by a caffeine test.  Br J Clin Pharmacol. 1994;  38 471-473
  PubMedGoogle Scholar
• 2 Centorrino F, Baldasserini R J, Kando J, Frankenburg F R, Volpicelli S A, Puopolo P R, Flood J. Serum concentrations of clozapine and its major metabolites: effects of cotreatment with Fluoxetine or Valproate.  Am J Psychiatry. 1994;  151 123-125
  CrossrefPubMedGoogle Scholar
• 3 Dose M. Behandlung der Therapieresistenzen mit Clozapin. In: Naber D, Müller-Spahn F (eds) Clozapin. Pharmakologie und Klinik eines atypischen Neuroleptikums.  Berlin, Heidelberg, New York, Tokyo; Springer 1995: 19-27
  Google Scholar
• 4 Edge S C, Markovitz J S, De Vane C L. Clozapine drug-drug interaction; a review of the literature.  Hum Psychopharmacol. 1997;  12 5-20
  PubMedGoogle Scholar
• 5 Facciolà G, Avenoso A, Scordo M G, Madia A G, Ventimiglia A, Perucca E, Spina E. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders.  Ther Drug Monit. 1999;  21 341-345
  CrossrefPubMedGoogle Scholar
• 6 Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition.  Biol Psychiatry. 1994;  36 487-488
  PubMedGoogle Scholar
• 7 Glue P, Banfield C H. Psychiatry, Psychopharmacology and P 450 s.  Hum Psychopharmacol. 1996;  11 97-114
  PubMedGoogle Scholar
• 8 Haller E, Binde R L. Clozapine and seizures.  Am J Psychiatry. 1990;  147 1069-1071
  PubMedGoogle Scholar
• 9 Levy R H, Rettenmeier A W, Anderson G D, Wilensky A J, Friel P N, Boillie T A. et al . Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of enevalproate, a hepatotoxic metabolite of valproic acid.  Clin Pharmacol Ther. 1990;  48 225-235
  PubMedGoogle Scholar
• 10 Longo L P, Salzman C. Valporic Acid Effects on Serum Concentrations of Clozapine and Norclozapine.  Am J Psychiatry. 1995;  152 650
  PubMedGoogle Scholar
• 11 Park B K, Kitterinham N R, Pirmohamed M, Tucker G T. Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications.  Br J Clin Pharmacol. 1996;  41 477-491
  CrossrefPubMedGoogle Scholar

Dr. med. Andreas Conca

Abteilung für Psychiatrie I LKH Rankweil

Valdunastraße 16

6830 Rankweil

Austria